With financial support from BARDA, Takeda's purified, inactivated, alum-adjuvanted Zika vaccine has entered human testing.
Gilead is introducing Sovaldi in China, where it faces mounting competitive pressure, at a steep discount.
Biocon has resolved FDA concerns about a plant in India, setting it and Mylan up to potentially win FDA approval for the first Herceptin biosimilar.
Pfizer exits a JV with China's Hisun Pharma, FDA approved the first digital medicine, and Astellas was added to a charity donation probe.
Astellas has joined the biopharma who's who of companies to disclose federal scrutiny for donations to charities that help patients cover drug costs.
Lupin has been trying for two years to bring its plant in Goa, India, up to FDA standards, but a new warning letter says more improvements are needed.
Cardinal Health has agreed to sell its China business to Shanghai Pharma for $557 million in cash.
Launched for lung cancer awareness month in November, the “tALK+” (Talk Positive) campaign focuses on the ALK-positive form of lung cancer.
Pfizer bowed out of a troubled joint venture with China's Hisun Pharma, which sells branded generic drugs in China.
Takeda, along with Lundbeck and Advocate Health Care, will study an app to track and measure patients’ experience on antidepressant therapies.